ReviewNature reviews. Microbiology2025
Fungal biofilms in human health and disease.
Review in Nature reviews. Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- A theranostic wearable laser-induced graphene-hydrogel dressing for synergistic treatment and real-time monitoring of dermatophytosis.Bioactive materials · 2026Article
- Amphotericin B-loaded polyphenolic nanoparticles for synchronous fungal eradication and immunomodulation in treating superficial fungal infections.Materials today. Bio · 2026Article
- COVID-19-Associated Fungal Co-Infections: Pathogenesis, Diagnostics, Biomarkers, and Therapeutic Strategies.Journal of clinical medicine · 2026Review
- Outbreaks of fluconazole-resistant Candida parapsilosis are driven by low-biofilm-producing isolates that emerge under host selection.PLoS biology · 2026Article
- A trade-off between fungal biofilm formation and persistence in the host.PLoS biology · 2026Article
- From Oral Candidiasis to Candidemia: A Review of Superficial to Invasive Progression.MicrobiologyOpen · 2026Review
- Negative control of Candida albicans biofilm formation by combined action of white-opaque regulator Wor2 and biofilm regulator Bcr1.G3 (Bethesda, Md.) · 2026Article
- Article
- An emergent biofilm program from inactivation of Candida albicans master regulators Efg1 and Ndt80.PLoS pathogens · 2026Article
- Efficacies of Conventional Antifungals and Complementary and Alternative Medicine as Single or Combination Therapies AgainstJournal of fungi (Basel, Switzerland) · 2026Article
- The Wor2 phenotypic switching regulator controls biofilm formation in Candida auris.NPJ biofilms and microbiomes · 2026Article
- Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges.International journal of pharmaceutics: X · 2026Review
- Article
- Ultrasound-triggered microbubble delivery of voriconazole for enhanced reduction of Candida albicans biofilms in vitro.Bone & joint research · 2026Article
- Surface colonization of Aureobasidium pullulans: a multimodal microscopy study toward living coating development.Scientific reports · 2026Article
- Profound cell wall remodeling inMicrobiology spectrum · 2026Article
- Acute high shear stress enhances fungal cell/substrate adhesion.Microbiology spectrum · 2026Article
- Review
- Potential Antifungal Activity of Retinoids Against Non-Microorganisms · 2026Article
- Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro.The Journal of antimicrobial chemotherapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increased use of implanted medical devices, use of immunosuppressants and an ageing population have driven the rising frequency of fungal biofilm-related diseases. Fungi are now recognized by the World Health Organization (WHO) as an emergent threat to human health, with most medically important species defined as critical or high-priority organisms capable of forming biofilms. Although we strive for a better understanding of diagnostic and therapeutic approaches to detect and treat these fungal diseases more generally, the issue of hard-to-treat biofilms is an ever-increasing problem. These are communities of interspersed cells that are attached to one another on a surface, such as a catheter, or trapped into a cavity such as a paranasal sinus. Biofilms are difficult to detect, difficult to remove and intrinsically tolerant to most antifungal agents. These factors can lead to devastating consequences for the patient, including unnecessary morbidity and mortality, need for reoperations and prolonged hospital stay. This Review describes the breadth and growing impact fungal biofilms have on patient management and explains the mechanisms promoting biofilm formation, focusing on how targeting these can improve therapeutic options.
Indexed as
Identifiers
39910237What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.